2011-03-17 18:06
Pressmeddelanden
2010-08-31 16:46 Från den 17 augusti tog Clas Lindbergson över som Managing Director Nordic för Eisai AB..Det har gått fyra år sedan det japanska läkemedelsföretaget etablerade sig i Norden. Idag, 25 anställda och sju produkter senare, är det dags att ta steget vidare in i nya sjukdomsområden under en ny ledning.
2010-08-24 11:58 Hatfield, UK, 24 August 2010 – Eisai today announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and under development for adjunctive treatment of partial seizures in patients with epilepsy.
2010-06-09 14:57 Global EMBRACE-studie jämförde eribulin med behandling enligt läkarens val
2010-06-07 17:11 Global EMBRACE Study Compared Eribulin to Treatment of Physician’s Choice
2010-04-01 12:00 LONDON, UK, 31 March 2010 — Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as ‘E7389’, for the treatment of locally advanced or metastatic breast cancer in Europe.
2009-12-21 07:30 Eisai Obtains Worldwide Rights to Develop, Market and Manufacture AKR-501, Therapeutic Agent for Thrombocytopenia
2009-12-21 07:00 Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Hauro Naito) today announced the completion of construction of the Eisai Knowledge Centre, India, the Company’s new manufacturing and process research base in India.
2009-11-10 07:00
2009-10-07 13:31 Den store andel af epilepsipatienter, der stadig får anfald trods medicinsk behandling, får nu en ny mulighed for at nedbringe deres anfaldsfrekvens. En ny tillægsbehandling Zebinix (eslicarbazepinacetat) til voksne patienter med partielle anfald giver således mulighed for nedsat anfaldsfrekvens og forhøjet livskvalitet med én pille om dagen.
